Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tn-Miner: Technology for the Discovery of Tumor-specific Glycopeptide Immunotherapy Targets.

NCT06629233 is registered in ClinicalTrials.gov with University Ghent as lead sponsor.

NCT NCT06629233
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06629233 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tn-Miner: Technology for the Discovery of Tumor-specific Glycopeptide Immunotherapy Targets.
Lead sponsor
University Ghent
Phase
Not applicable
Overall status
Enrolling by invitation
Start date
September 25, 2024
Completion date
December 31, 2025
Enrollment
36 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

estrogen receptor positive breast cancer